| Outcome Measures: |
Primary: Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations, Safety Assessment evaluated through adverse events, laboratory evaluations, vital signs, ECGs, and physical examination., SAD: Up to Day 8 and MAD: Up to Day 35 | Secondary: Pharmacokinetic Parameters: AUC0-24, AUC from time 0 to 24 hour dosing interval, SAD: Up to Day 3 and MAD: Up to Day 30|Pharmacokinetic Parameters: AUC0-tlast, AUC from time 0 to the time of last quantifiable non-zero concentration, SAD: Up to Day 3|Pharmacokinetic Parameters: AUC0-tau, AUC over a dosing interval from time 0 to time of last quantifiable concentration, MAD: Up to Day 30|Pharmacokinetic Parameters: AUC0-infinity, AUC from time 0 extrapolated to infinity, SAD: Up to Day 3|Pharmacokinetic Parameters: Cmax, Maximum observed plasma concentration, SAD: Up to Day 3 and MAD: Up to Day 30|Pharmacokinetic Parameters: C24, Observed concentration at 24 hours post dose, SAD: Up to Day 3 and MAD: Up to Day 30|Pharmacokinetic Parameters: Ctau, Observed concentration at the end of the dosing interval, MAD: Up to Day 30|Pharmacokinetic Parameters: tmax, Time of the maximum observed plasma concentration, SAD: Up to Day 3 and MAD: Up to Day 30|Pharmacokinetic Parameters: tlag, Lag time (time delay between dosing and first observed plasma concentration), SAD: Up to Day 3 and MAD: Up to Day 30|Pharmacokinetic Parameters: t1/2, Apparent terminal elimination half-life, SAD: Up to Day 3 and MAD: Up to Day 30|Pharmacokinetic Parameters: Clast, Last measurable non-zero concentration, SAD: Up to Day 3|Pharmacokinetic Parameters: tlast, Time of last measurable non-zero concentration, SAD: Up to Day 3|Pharmacokinetic Parameters: CL/F, Apparent Clearance, SAD: Up to Day 3 and MAD: Up to Day 30|Pharmacodynamic Parameters: AUC0-4 for glucose, AUC from time 0 to 4 hour dosing interval, MAD: Up to Day 30|Pharmacodynamic Parameters: AUC0-4 for insulin, AUC from time 0 to 4 hour dosing interval, MAD: Up to Day 30|Pharmacodynamic Parameters: AUC0-4 for glucagon, AUC from time 0 to 4 hour dosing interval, MAD: Up to Day 30|Pharmacodynamic Parameters: AUC0-4 for C-peptide, AUC from time 0 to 4 hour dosing interval, MAD: Up to Day 30|Pharmacodynamic Parameters: Fasting plasma glucose, Change from baseline, MAD: Up to Day 30|Pharmacodynamic Parameters: Mean daily glucose, Change from baseline, MAD: Up to Day 30|Pharmacodynamic Parameters: Body Weight and Waist Circumference, Change from baseline, MAD: Up to Day 30|Pharmacodynamic Parameters: Fasting plasma glucose homeostatic model assessment, Fasting plasma glucose homeostatic model assessment, MAD: Up to Day 30|Pharmacodynamic Parameters: Fasting plasma insulin homeostatic model assessment, Fasting plasma insulin homeostatic model assessment, MAD: Up to Day 30
|
